Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy — Bernhard Scheiner (2024) | RDL Network
Outcome and management of patients with hepatocellular carcinoma who achieved a complete response to immunotherapy-based systemic therapy
Article 2024 en
Authors
BS
Bernhard Scheiner
BK
Beodeul KANG
LB
Lorenz Balcar
Abstract
1 min read
Overall survival and recurrence-free survival of patients with CR-mRECIST-only and CR-RECISTv1.1 were excellent, and 6 of 7 patients with CR-mRECIST-only who underwent surgical conversion therapy had pathological CR. Despite potential limitations, these findings support the use of mRECIST in the context of immunotherapy for clinical decision-making. When considering ICI discontinuation, treatment for at least 6 months beyond CR seems advisable.
Bernhard Scheiner, Beodeul Kang, Lorenz Balcar, Iulian Radu, Florian P. Reiter, G. Adžić, Jiang Guo, Xu Gao, Xiaoyan Yuan, Long Cheng, Joao Gorgulho, Najib Ben Khaled, Maximilian Schultheiß, Friedrich Sinner, Katharina Pomej, Anna Saborowski, Birgit Schwacha‐Eipper, Valentina Zarka, Katharina Lampichler, Naoshi Nishida, P-C. Lee, A. Krall, Anum Saeed, Vera Himmelsbach, Giulia Tesini, Yuming Huang, C. Vivaldi, Gabriele Masi, Arndt Vogel, Kornelius Schulze, Michael Trauner, Rudolf Stauber, Masatoshi Kudo, Jeroen Dekervel, Neehar D. Parikh, Jean‐François Dufour, Juraj Prejac, Andreas Geier, Bertram Bengsch, Johann von Felden, Marino Venerito, A. Philipp, Fabian Finkelmeier, Feng Ji, Hung-Wei Wang, L. Rimassa, David J. Pinato, M. Bouattour, Hong Jae Chon, Matthias Pinter
Masatoshi Kudo, Robert Montal, Richard S. Finn, Florian Castet, Kazuomi Ueshima, Naoshi Nishida, Philipp K. Haber, Youyou Hu, Yasutaka Chiba, Myron Schwartz, Tim Meyer, Riccardo Lencioni, Josep M. Llovet
Discussion(0)
No comments yet. Be the first to comment.